Metformin plus chemotherapy versus chemotherapy alone in the first-line treatment of HER2-negative metastatic breast cancer. The MYME randomized, phase 2 clinical trial

2019

Purpose To investigate the efficacy of metformin (M) plus chemotherapy versus chemotherapy alone in metastatic breast cancer (MBC).

Keywords:

Correction
Source
Cite
Save
Machine Reading By IdeaReader

29

References

38

Citations